Arcapta Neohaler
Arcapta Neohaler is a long-acting beta2-adrenergic agonist (LABA) inhalation powder used to control and prevent symptoms like wheezing and shortness of breath caused by ongoing lung disease (COPD). It works by relaxing the muscles around the airways in the lungs so that they open up and make breathing easier.
Dosage by Body Weight
The recommended dosage is the inhalation of the contents of one 75 mcg capsule once daily using the Neohaler inhaler. It should be administered at the same time each day. The capsules must only be inhaled orally using the Neohaler device and must not be swallowed.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy have not been established in pediatric populations. COPD does not typically occur in children.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy have not been established in pediatric populations. COPD does not typically occur in children.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy have not been established in pediatric populations. COPD does not typically occur in children.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy have not been established in pediatric populations. COPD does not typically occur in children.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy have not been established in pediatric populations. COPD does not typically occur in children.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and efficacy have not been established in pediatric populations. COPD does not typically occur in children. |
| 5-7 kg | Not recommended | N/A | Safety and efficacy have not been established in pediatric populations. COPD does not typically occur in children. |
| 8-10 kg | Not recommended | N/A | Safety and efficacy have not been established in pediatric populations. COPD does not typically occur in children. |
| 11-15 kg | Not recommended | N/A | Safety and efficacy have not been established in pediatric populations. COPD does not typically occur in children. |
| 16-20 kg | Not recommended | N/A | Safety and efficacy have not been established in pediatric populations. COPD does not typically occur in children. |
Formulation
Purpose
Long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Generic Name
IndacaterolScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.